Skip to main content
SSO 2024 Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded for On-Demand Viewing
Recorded for On-Demand Viewing
Back

Andrea V. Barrio, MD

Associate Attending/Dept. of Surgery/Breast Service
Memorial Sloan Kettering Cancer Center
New York, New York, United States

Andrea V. Barrio, MD, FACS
Associate Attending
Breast Service, Department of Surgery
Memorial Sloan Kettering Cancer Center




Andrea V. Barrio, MD, FACS is an Associate Attending with the Breast Service, Department of Surgery at Memorial Sloan Kettering Cancer Center, and an Associate Professor of Surgery at Weill Cornell Medical College. Dr. Barrio received her BS degree from the University of California, Los Angeles and her MD from the University of California, Los Angeles School of Medicine, where she was elected to the membership of the Alpha Omega Alpha Honor Medical Society. She completed her surgical residency at New York Presbyterian Hospital, Weill Cornell Medical Center, followed by one year of breast surgical oncology fellowship training at Memorial Sloan Kettering Cancer Center.

Dr. Barrio specializes in the surgical treatment of breast cancer. Her research focuses on decreasing the morbidity of breast cancer treatment, specifically lymphedema, which is a consequence of more-extensive axillary surgery. To date, she has led/co-led several studies on incidence and risk factors for lymphedema, including the role of inflammation in lymphedema development. She has also focused on methods to prevent lymphedema using neoadjuvant chemotherapy in clinically node-positive patients to reduce the extent of axillary surgery and minimize the need for axillary lymph node dissection.
She serves as PI on a lymphedema screening study in women undergoing breast cancer treatment to prospectively determine the incidence of upper-extremity lymphedema after axillary lymph node dissection and to evaluate the role of inflammatory biomarkers, as well as traditional patient and treatment factors, in the pathogenesis of lymphedema. She also serves as PI on a multi-institution prospective study evaluating the accuracy of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Presentation(s):